Abstract:
Cancer is a complex disease since it is adaptive
in such a way that it can promote proliferation and
invasion by means of an overactive cell cycle and in turn
cellular division which is targeted by antimitotic drugs
that are highly validated chemotherapy agents. However,
antimitotic drug cytotoxicity to non-tumorigenic cells and
multiple cancer resistance developed in response to drugs
such as taxanes and vinca alkaloids are obstacles faced in
both the clinical and basic research field to date. In this
review, the classes of antimitotic compounds, their mechanisms
of action and cancer cell resistance to chemotherapy
and other limitations of current antimitotic compounds are
highlighted, as well as the potential of novel 17-β estradiol
analogs as cancer treatment.
